Профилактика рака шейки матки: методы ранней диагностики и новые скрининговые технологии (Клиническая лекция)

1. Прилепская В.Н., Кондриков Н.И., Бебнева Т.Н. Патология шейки матки. Диагностические возможности цитологического скрининга. Акуш. и гин. 1999; 3: 45–50.
2. Кулаков В.И., Аполихина И.А., Прилепская В.Н., Сухих Г.Т. Современные подходы к диагностике папилломавирусной инфекции гениталий женщин и их значение для скрининга рака шейки матки. Гинекология. 2000; 1 (2): 4–8.
3. Козаченко В.П. Рак шейки матки. Совр. онкол. 2001; 2 (2): 2 4.
4. Роговская С.И., Прилепская В.Н. Профилактика папилломавирусной инфекции и рака шейки матки. Гинекология. 2005; 1 (7): 22–6.
5. Бебнева Т.Н., Прилепская В.Н. Папилломавирусная инфекция и патология шейки матки. Гинекология. 2001; 3 (3): 77–81.
6. Acladius NN, Sutton C, Mandal D et al. Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepithelial neoplasia (CIN). Int J Cancer 2002; 98 (3): 435–9.
7. Agnantis NJ, Sotiriadis A, Paraskevaidis E. The current status of HPV DNA testing. Eur J Gynaecol Oncol 2003; 24: 351–603.
8. Boyle P, Autier P, Bartelink H et al. European code against cancer and scientific justification: third version (2003). Ann Oncol 2003; 14: 973–1005.
9. Davey E, Barratt A, Irwig et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 2006; 376: 122–32.
10. Franco El, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005; 23: 2388–94.
11. Frazer Ian H., Cox J. Thomas, Mayeaux Edward John et al. Advances in Prevention  of Cervical Cancer and Other Human Papillomavirus-Related Diseases. The Pediatric Infectious Diseases Journal, Vol 25, No 2, Suppl. February 2006.
12. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent LI virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757–65.
13. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4,5 years of a bivalent LI virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised controlled trial. Lancet 2006.
14. Klaes R et al. Overexpression of p16ink4a as a specific marker for displastic and neoplastic cells in cervical cancer. Iny J Cancer 2001; 92:276–84.
15. Nuovo J, Melnikow J, Howell LP. New tests for cervical cancer screening. Am Fam Physician 2001; 64: L780–6.
16. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364: 249–56.
17. Sankaranarayanan R, Gaffikin L, Jacob M et al. A critical assessment of screening methods for cervical neoplasia. Int J Gynecol Obstet 2005; 89: S4–l2.
18. Saslow D, Runowicz CD, Solomon D et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002; 52: 342–62. http://CAonline.AmCancerSoc. org. Accessed 19 June 2006.
19. Solomon D, Davey D, Kurman R et al. The 2001 Bethesda System. Terminology for reporting results of cervical cytology. JAMA 2002; 287 (16): 2114–8.
20. Steenbergen RDM, C Meijer,P Snijers. Molecular Markers for Cervical Cancer. In book Mosonego.... 2006.
21. World Health Organization (WHO). Comprehensive Cervical Cancer Control. A guide to essential practice. Geneva: WHO 2006.
22. Villa LL, Costa RLR, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 virus-like particle vaccine through 5 years of follow-up. British Journal of Cancer (2006) 96, 1459–1466.

В.Н.Прилепская

ФГУ Научный центр акушерства, гинекологии и перинатологии Федерального агентства по высокотехнологичной 
медицинской помощи, Москва